Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PML in a patient with lymphocytopenia treated with dimethyl fumarate.

× No keyword cloud information.

80 in total

Review 1. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors: Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal: Nat Rev Neurol Date: 2015-09-15 Impact factor: 42.937

Review 2. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors: Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal: Neurotherapeutics Date: 2016-01 Impact factor: 7.620

3. [Current immunotherapy of multiple sclerosis].

Authors: F Paul; K Ruprecht
Journal: Nervenarzt Date: 2015-08 Impact factor: 1.214

Review 4. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors: Ralf A Linker; Aiden Haghikia
Journal: Ther Adv Chronic Dis Date: 2016-06-10 Impact factor: 5.091

Review 5. Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors: C McNamara; G Sugrue; B Murray; P J MacMahon
Journal: AJNR Am J Neuroradiol Date: 2017-04-13 Impact factor: 3.825

6. [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors: A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal: Nervenarzt Date: 2015-08 Impact factor: 1.214

Review 7. Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.

Authors: Lori Mayer; Mary Kay Fink; Carrie Sammarco; Lisa Laing
Journal: Drug Saf Date: 2018-04 Impact factor: 5.606

8. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors: Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal: J Neurol Date: 2016-05-18 Impact factor: 4.849

Review 9. Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors: J Nicholas Brenton; Brenda L Banwell
Journal: Neurotherapeutics Date: 2016-01 Impact factor: 7.620

Review 10. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors: Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal: Ann Neurol Date: 2015-07-31 Impact factor: 10.422